ESMO26: KEYNOTE-C93 backs chemo-free Keytruda in dMMR endometrial cancer - Pharmaceutical Technology

Phase III results support chemotherapy-free first-line Keytruda in dMMR but leave the most clinically relevant comparison untested. Phase III results support chemotherapy-free first-line Keytruda in dMMR but leave the most clinically relevant comparison untested. After a median follow-up of 36.7 months, median PFS reached 38.2 for Keytruda versus 8.4 months for carboplatin plus paclitaxel. Credit: megaflopp/Shutterstock. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading site for news and procurement in the pharmaceutical industry…

Source: Pharmaceutical Technology